Nagayama, K. and Hirooka, Y. (2025) Changes in the Mechanical Environment of the Nucleus with Cell Crowding and Its Effects on DNA Damage Resistance. Journal of Biosciences and Medicines, 13, 230-242.

Vodafone had requested a refund of prepaid taxes with interest, totaling around Rs 1,600 crore, for the assessment year ...

Intra-Cellular Therapies Inc (ITCI) stock saw a decline, ending the day at $126.2 which represents a decrease of $-0.06 or -0.05% from the prior close of $126.26. The stock opened at $126.65 and ...

"Berries offer an exceptional combination of nutrients and compounds that support longevity and healthy aging. They’re ...

High-speed internet is not a luxury—it is a lifeline for economic opportunity. More than $1.3 billion was invested in the BPO ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion to enhance its neuroscience drug portfolio.

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...

And GSK said it would pay up to $1.15 billion privately-held IDRx, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of GIST, which stands for Gastrointestinal ...